News | November 06, 2025
Marksans Pharma’s UK Arm Relonchem secures MHRA nod for Exemestane 25mg Tablets
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Glenmark will begin distribution in November 2025
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
AI-powered cardiometabolic wellness platform for India’s workforce
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Subscribe To Our Newsletter & Stay Updated
